Showing results (251-260 of 277) with videos related to
Sort By:
Pageof 28
Hepatology International|June 24, 2022
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|December 1, 2022
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2022
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practiceTakaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Journal of Gastroenterology|August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varicesFujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumabAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Reports (Hoboken, N.J.)|April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Pageof 28